Helix Biopharma Corp. Announces Management and Board Changes
Yahoo! Finance
RICHMOND HILL, ON / ACCESSWIRE / March 22, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced that Frank Michalargias has notified the Board of Directors of the Company of his intention to resign from the position of Chief Financial Officer, effective no later than May 15, 2022.
Continue Reading